Navigation Links
Research yields new clues to how brain cancer cells migrate and invade
Date:5/1/2012

Researchers have discovered that a protein that transports sodium, potassium and chloride may hold clues to how glioblastoma, the most common and deadliest type of brain cancer, moves and invades nearby healthy brain tissue. The findings, reported 1 May in the online, open-access journal PLoS Biology, also suggest that a cheap FDA-approved drug already on the market could slow movement of glioblastoma cells.

"The biggest challenge in brain cancer is the migration of cancer cells. We can't control it," says study leader Alfredo Quinones-Hinojosa, M.D., an associate professor of neurosurgery and oncology at the Johns Hopkins University School of Medicine. "If we could catch these cells before they take off into other parts of the brain, we could make malignant tumors more manageable, and improve life expectancy and quality of life. This discovery gives us hope and brings us closer to a cure."

Glioblastoma, which is diagnosed in roughly 10,000 Americans each year, is so aggressive that the average life expectancy after diagnosis is just 15 months, Quinones says. The cancer spreads to healthy brain tissue so quickly and completely that surgical cures are virtually impossible and advances in radiation and chemotherapy have been slow in coming.

In a search for ways to prevent or limit the spread, and stop lethal recurrence of the tumor, the researchers focused on a protein called NKCC1 in human tumor cells in the laboratory and also in tumor cells injected into mice. NKCC1 exchanges sodium, potassium and chloride ions, together with water and regulates cell volume.

Quinones-Hinojosa and his team found that cells with more NKCC1 appear to move farther because the protein made it easier for tumor cells to propel themselves through tissue. The more of this protein in the tumor cell, they discovered, the faster the glioblastoma cells were able to travel. When NKCC1 was absent, they noted that the cells had larger focal adhesions, which allow the cells to attach to surrounding cells. Larger adhesions, he says, appear to keep the cells more anchored in place, while smaller ones made cells more mobile and allowed for more migration.

In their experiments, the researchers blocked the protein and were able to slow the migration of the tumor cells. Less mobility, Quinones-Hinojosa says, means less invasion of surrounding tissue.

To block the channel, the team used the diuretic bumetanide, a simple water pill routinely used to reduce swelling and fluid retention. Added to either tumor cells in the laboratory, or to human tumor cells in mice, the drug blocked the NKCC transporter and slowed the pace of cell movement. If the cells were made less invasive, Quinones notes, tumors would be easier to surgically remove.

The researchers were also able to correlate human tumor grade with levels of NKCC1. The less aggressive the tumor, they discovered, the smaller the amount of the protein present in the cells. This suggests that NKCC1 may not only contribute to the increased invasiveness of tumors, but also serve as a potential marker for diagnosis.


'/>"/>
Contact: Rachel Jarmy
rjarmy@plos.org
44-122-344-2837
Public Library of Science
Source:Eurekalert

Related medicine news :

1. Embedded Mobile & M2M Device revenues to Rise to Almost $19 Billion Globally by 2014, Says Juniper Research
2. 2010 HSR Impact Award recognizes surgical safety research
3. MSU launches first anti-counterfeiting research program
4. Researchers map all the fragile sites of the yeast Saccharomyces cerevisiaes genome
5. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
6. Researchers discover new way to kill pediatric brain tumors
7. Family Research Council: Planned Parenthood Report Oversexualizes Ten-Year-Olds, Undermines Parental Authority
8. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
9. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
10. International Diabetes Federation awards $2 million to 9 global diabetes research projects
11. Gladstones Robert Mahley to receive Research!America advocacy award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Mother Nature isn’t the only mom ... fruits and vegetables. , Celebrate these women with more than just a bouquet ... with these five garden-themed options. , Vibrant, Edible, Compact Plants from BrazelBerries: , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... to identify, fund and implement ideas aimed at improving care and reducing readmission ... “Part of our vision for Trinity Health is to drive innovation that transforms ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and Vancouver, WA, has announced the latest beneficiary of their ongoing community ... and their Mammography Program, which provides free mammograms and diagnostic breast care ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  It,s time for an upgrade. There are many medical recorders on the market ... the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned ... manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... BRIDGEWATER, New Jersey , May 4, 2016 /PRNewswire/ ... today its successful completion of an alternative public offering ... its wholly owned operating company, Valeritas, Inc. and a ... unregistered common stock at $5.00 per share. ... completed on May 3, 2016, Valeritas Holdings, Inc. will ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology: